START亚组分析及ICS在中国的应用.pptVIP

中国区患者布地奈德治疗组严重哮喘相关不良事件风险较安慰剂组降低63%，比总体人群更明显（63% vs 44%）Compared to placebo, Budesonide reduces the risk of severe asthma-related adverse events by 63%. 严重哮喘相关不良事件Severe Asthma-Related Events (SARE) Chen YZ, Chen P, Zhao DY, et al. Effectiveness of long-term budesonide in Chinese patients with mild persistent asthma. Data on File. START总体人群 风险 44% 到首次严重哮喘相关不良事件的时间 布地奈德 安慰剂 风险63% 中国区 Time to first Severe Asthma-Related Events (SARE) 哮喘总体控制 Asthma Control  Chen YZ, Chen P, Zhao DY, et al. Effectiveness of long-term budesonide in Chinese patients with mild persistent asthma. Data on File. 与安慰剂组相比： 布地奈德组患者的无症状天数显著增多(p0.0001) 无症状天数比例（%） 安慰剂 布地奈德 时间 无症状天数比 Symptom-free days % ↑  额外激素类药物使用 Use of additional GCs 安慰剂 布地奈德 额外激素使用风险58% 与安慰剂组相比： 布地奈德治疗显著延长了到首次额外糖皮质激素使用的时间，使额外激素使用风险总体降低了58% BUD treatment reduce the risk of additional non-study GCs usage of 58% (HR: 0.42, 95% CI: 0.33–0.55; p0.0001). Chen YZ, Chen P, Zhao DY, et al. Effectiveness of long-term budesonide in Chinese patients with mild persistent asthma. Data on File. 到首次额外糖皮质激素使用的时间Time to First addition of non-study glucocorticosteroids（GCs） * group Randomisation 3?months 12?months 24?months 36?months ICS Budesonide 26 (6.0) 13 (3.0) 10 (2.4) 14 (3.4) 10 (2.5) Placebo 27 (6.2) 27 (6.3) 44 (11) 56 ( 14) 40 (11) Oral or systemic corticosteroid Budesonide 26 (6.0) 12 (2.8) 9 (2.1) 9 (2.2) 3 (0.7) Placebo 21 (4.8) 28 (6.5) 19 (4.7) 19 (4.9) 14 (3.7) Short-acting β2 agonist Budesonide 193 (44) 113 (26) 90 (21) 79 (19) 65 (16) Placebo 215 (50) 178 (41) 152 (38) 125 (32) 98 (26) Xanthine Budesonide 124 (29) 65 (15) 40 (9.5) 36 (8.8) 26 (6.5) Placebo 135 (31) 92 (21) 67 (17) 63 (16) 38 (10) 安慰剂组患者需要额外哮喘药物治疗的使用例数更多. A greater number of patients in the placebo group received additional treatment. 额外其他哮喘药物使用 Use of additional asthma medications Chen YZ, Chen P, Zhao DY, et al. Effectiveness of long-term budesonide in Chinese patients with mild persistent asthma. Data on File. 耐受性 Tolerance 两组间患者报告的与哮喘无关